keyword
MENU ▼
Read by QxMD icon Read
search

first line crizotinib versus chemotherapy in alk-positive lung cancer

keyword
https://www.readbyqxmd.com/read/27022118/intracranial-efficacy-of-crizotinib-versus-chemotherapy-in-patients-with-advanced-alk-positive-non-small-cell-lung-cancer-results-from-profile-1014
#1
Benjamin J Solomon, Federico Cappuzzo, Enriqueta Felip, Fiona H Blackhall, Daniel B Costa, Dong-Wan Kim, Kazuhiko Nakagawa, Yi-Long Wu, Tarek Mekhail, Jolanda Paolini, Jennifer Tursi, Tiziana Usari, Keith D Wilner, Paulina Selaru, Tony S K Mok
PURPOSE: Intracranial efficacy of first-line crizotinib versus chemotherapy was compared prospectively in the phase III PROFILE 1014 study in ALK-positive non-small-cell lung cancer. PATIENTS AND METHODS: Patients were randomly assigned to receive crizotinib (250 mg twice daily; n = 172) or chemotherapy (pemetrexed 500 mg/m(2) plus cisplatin 75 mg/m(2) or carboplatin at area under the curve 5 to 6, every 3 weeks for ≤ six cycles; n = 171). Patients with stable treated brain metastases (tBM) were eligible...
August 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/26880708/is-there-a-progression-free-survival-benefit-of-first-line-crizotinib-versus-standard-chemotherapy-and-second-line-crizotinib-in-alk-positive-advanced-lung-adenocarcinoma-a%C3%A2-retrospective-study-of-chinese-patients
#2
Shaohua Cui, Yizhuo Zhao, Lili Dong, Aiqin Gu, Liwen Xiong, Jialin Qian, Wei Zhang, Yanjie Niu, Feng Pan, Liyan Jiang
Although crizotinib has demonstrated promising efficacy and acceptable toxicity in patients with advanced non-small cell lung cancer (NSCLC), the available evidence in Chinese populations is currently limited. This study compared the progression-free survival (PFS) of Chinese patients with anaplastic lymphoma kinase (ALK)-positive, advanced lung adenocarcinoma who received first-line crizotinib therapy with that of patients who received first-line standard chemotherapy, and also the PFS benefit of first-line versus second-line crizotinib treatment...
June 2016: Cancer Medicine
https://www.readbyqxmd.com/read/26816533/crizotinib-versus-platinum-based-double-agent-chemotherapy-as-the-first-line-treatment-in-advanced-anaplastic-lymphoma-kinase-positive-lung-adenocarcinoma
#3
Quan Zhang, Na Qin, Jinghui Wang, Jialin Lv, Xinjie Yang, Xi Li, Jingying Nong, Hui Zhang, Xinyong Zhang, Yuhua Wu, Shucai Zhang
BACKGROUND: To explore the efficacy and safety of crizotinib versus platinum-based double agent chemotherapy as the first-line treatment in patients with advanced anaplastic lymphoma kinase (ALK)-positive lung adenocarcinoma. METHOD: We retrospectively analyzed data from 19 patients with advanced ALK-positive lung adenocarcinoma who had received no previous systemic treatment for advanced disease. Seven patients received oral crizotinib at a dose of 250 mg twice daily; 12 patients were administered standard chemotherapy (pemetrexed, paclitaxel, vinorelbine or gemcitabine plus either cisplatin or carboplatin) every three weeks for up to six cycles...
January 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/26466011/first-line-crizotinib-versus-chemotherapy-in-alk-positive-lung-cancer
#4
(no author information available yet)
No abstract text is available yet for this article.
October 15, 2015: New England Journal of Medicine
https://www.readbyqxmd.com/read/26294238/role-of-anaplastic-lymphoma-kinase-inhibition-in-the-treatment-of-non-small-cell-lung-cancer
#5
REVIEW
Katie Croegaert, Jill M Kolesar
PURPOSE: Published data on the clinical efficacy, safety, dosage and administration, and costs of the anaplastic lymphoma kinase (ALK) inhibitors crizotinib and ceritinib in the treatment of non-small-cell lung cancer (NSCLC) are reviewed and compared. SUMMARY: The ALK protein functions as a transmembrane receptor tyrosine kinase; rearrangements of the ALK gene are associated with the development of NSCLC with adenocarcinoma histology. Crizotinib is an oral tyrosine kinase inhibitor approved in 2011 as a first-line therapy for patients with metastatic ALK mutation-driven NSCLC...
September 1, 2015: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/25470694/first-line-crizotinib-versus-chemotherapy-in-alk-positive-lung-cancer
#6
RANDOMIZED CONTROLLED TRIAL
Benjamin J Solomon, Tony Mok, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari, Shrividya Iyer, Arlene Reisman, Keith D Wilner, Jennifer Tursi, Fiona Blackhall
BACKGROUND: The efficacy of the ALK inhibitor crizotinib as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non-small-cell lung cancer (NSCLC) is unknown. METHODS: We conducted an open-label, phase 3 trial comparing crizotinib with chemotherapy in 343 patients with advanced ALK-positive nonsquamous NSCLC who had received no previous systemic treatment for advanced disease. Patients were randomly assigned to receive oral crizotinib at a dose of 250 mg twice daily or to receive intravenous chemotherapy (pemetrexed, 500 mg per square meter of body-surface area, plus either cisplatin, 75 mg per square meter, or carboplatin, target area under the curve of 5 to 6 mg per milliliter per minute) every 3 weeks for up to six cycles...
December 4, 2014: New England Journal of Medicine
https://www.readbyqxmd.com/read/22887466/pemetrexed-based-chemotherapy-in-patients-with-advanced-alk-positive-non-small-cell-lung-cancer
#7
MULTICENTER STUDY
A T Shaw, A M Varghese, B J Solomon, D B Costa, S Novello, M Mino-Kenudson, M M Awad, J A Engelman, G J Riely, V Monica, B Y Yeap, G V Scagliotti
BACKGROUND: Anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) is highly responsive to crizotinib. To determine whether ALK-positive NSCLC is also sensitive to pemetrexed, we retrospectively evaluated progression-free survival (PFS) of ALK-positive versus ALK-negative patients who had been treated with pemetrexed-based chemotherapy for advanced NSCLC. PATIENTS AND METHODS: We identified 121 patients with advanced, ALK-positive NSCLC in the USA, Australia, and Italy...
January 2013: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/21336183/anaplastic-lymphoma-kinase-gene-rearrangements-in-non-small-cell-lung-cancer-are-associated-with-prolonged-progression-free-survival-on-pemetrexed
#8
D Ross Camidge, Scott A Kono, Xian Lu, Sonia Okuyama, Anna E Barón, Ana B Oton, Angela M Davies, Marileila Varella-Garcia, Wilbur Franklin, Robert C Doebele
HYPOTHESIS: To explore whether the progression-free survival (PFS) with pemetrexed differs between anaplastic lymphoma kinase (ALK)-positive and other major molecular subtypes of non-small cell lung cancer. METHODS: In an ALK-enriched population, patients with metastatic non-small cell lung cancer were screened by ALK fluorescence in situ hybridization and for epidermal growth factor receptor (EGFR) and KRAS mutations. Triple-tested, pemetrexed-treated patients (monotherapy or combination therapy) were identified and PFS with pemetrexed captured retrospectively...
April 2011: Journal of Thoracic Oncology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"